Accumulated Other Comprehensive Income (Loss) (Tables)

6 Months Ended

Jun. 30, 2023

Equity [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss)

The following tables summarize the changes in AOCI, net of tax by component:

	June 30, 2023
(In millions)	Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax		Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax		Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax		Currency Translation Adjustments		Total
Balance, December 31, 2022	$	(15.7)	$	15.1	$	(1.1)	$	(163.2)	$	(164.9)
Other comprehensive income (loss) before reclassifications	(0.2)		(10.1)		0.7		18.7		9.1
Amounts reclassified from AOCI	1.4		(18.4)		—		—		(17.0)
Net current period other comprehensive income (loss)	1.2		(28.5)		0.7		18.7		(7.9)
Balance, June 30, 2023	$	(14.5)	$	(13.4)	$	(0.4)	$	(144.5)	$	(172.8)

	June 30, 2022
(In millions)	Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax		Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax		Gains (Losses) on Net Investment Hedges, Net of Tax(1)		Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax		Currency Translation Adjustments		Total
Balance, December 31, 2021	$	(2.2)	$	53.8	$	25.5	$	(44.8)	$	(139.0)	$	(106.7)
Other comprehensive income (loss) before reclassifications	(19.1)		129.5		12.6		2.7		(94.9)		30.8
Amounts reclassified from AOCI	1.1		(56.4)		(38.1)		—		58.9		(34.5)
Net current period other comprehensive income (loss)	(18.0)		73.1		(25.5)		2.7		(36.0)		(3.7)
Balance, June 30, 2022	$	(20.2)	$	126.9	$	—	$	(42.1)	$	(175.0)	$	(110.4)

(1) Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read Note 2, Dispositions, to these condensed consolidated financial statements.

Reclassification out of Accumulated Other Comprehensive Income

The following table summarizes the amounts reclassified from AOCI:

(In millions)	Amounts Reclassified from AOCI								Income Statement Location
	For the Three Months Ended June 30,				For the Six Months Ended June 30,
	2023		2022		2023		2022
Gains (losses) on securities available for sale	$	(1.3)	$	(0.8)	$	(1.8)	$	(1.4)	Other (income) expense
	0.3		0.2		0.4		0.3		Income tax (benefit) expense
Gains (losses) on cash flow hedges	2.4		44.6		20.0		65.5		Revenue
	1.4		(2.4)		0.9		(2.7)		Operating expense
	(0.1)		(0.1)		(0.2)		(0.2)		Other (income) expense
	(0.4)		(4.2)		(2.3)		(6.2)		Income tax (benefit) expense
Gains (losses) on net investment hedges(1)	—		39.2		—		38.1		Other (income) expense
Currency translation adjustments	—		(58.9)		—		(58.9)		Other (income) expense
Total reclassifications, net of tax	$	2.3	$	17.6	$	17.0	$	34.5

(1) Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read Note 2, Dispositions, to these condensed consolidated financial statements.